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Summary
 
B-1 lymphocytes represent a distinct B cell subset with characteristic features that include self-
renewing capacity and unusual mitogenic responses. B-1 cells differ from conventional B cells
in terms of the consequences of phorbol ester treatment: B-1 cells rapidly enter S phase in re-
sponse to phorbol ester alone, whereas B-2 cells require a calcium ionophore in addition to
phorbol ester to trigger cell cycle progression. To address the mechanism underlying the varied
 
proliferative responses of B-1 and B-2 cells, we evaluated the expression and activity of the
G1 cell cycle regulator, cyclin D2, and its associated cyclin-dependent kinases (Cdks). Cyclin
D2 expression was upregulated rapidly, within 2–4 h, in phorbol ester–stimulated B-1 cells, in
a manner dependent on intact transcription/translation, but was not increased in phorbol ester–
stimulated B-2 cells. Phorbol ester–stimulated cyclin D2 expression was accompanied by the
formation of cyclin D2–Cdk4, and, to a lesser extent, cyclin D2–Cdk6, complexes; cyclin D2–
containing complexes were found to be catalytically functional, in terms of their ability to
phosphorylate exogenous Rb in vitro and to specifically phosphorylate endogenous Rb on
 
serine
 
780
 
 in vivo. These results strongly suggest that the rapid induction of cyclin D2 by a nor-
mally nonmitogenic phorbol ester stimulus is responsible for B-1 cell progression through G1
phase. The ease and rapidity with which cyclin D2 responds in B-1 cells may contribute to the
proliferative features of this subset.
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B
 
-1 cells constitute a unique B lymphocyte subset, orig-
inally distinguished from conventional B (B-2) cells by
low level expression of the pan-T cell surface glycoprotein,
CD5, but now known to exhibit many additional charac-
teristic features that are both phenotypic and functional in
 
nature (for review, see references 1–3). B-1 cells appear early
in development and contribute substantial proportions of
nonimmune (resting) IgM and IgA that are repertoire re-
stricted. Early adoptive transfer experiments suggested that
B-1 cells represent a separate lymphocyte lineage whose
precursors are not found in adult murine bone marrow (1–
3). Instead, repopulation of B-1 cells occurred only in mice
that had also received surface Ig (sIg)
 
1
 
-positive B-1 cells,
thereby defining the capacity of B-1 cells for “self-renewal.”
Aberrations in this process may be associated with the oc-
currence of clonal expansions of B-1 cells (4, 5). More re-
cent studies have raised the possibility that B-1 cells result
from particular sIg signaling of a relatively mature B cell;
this is supported by in vitro studies showing that B-2 cells
acquire CD5 expression after sIg cross-linking, and in vivo
 
studies demonstrating an overabundance of B-1 cells in
mice transgenic for certain B cell receptors (6, 7). In keep-
ing with this, B-1 cells bear some features of previously ac-
tivated B cells, including low density, surface expression of
CD44 and IL-5R, and nuclear, activated signal transducer
and activator of transcription (STAT)1 and STAT3 (8–10).
However, numerous other molecular and transcriptional
markers for activation are lacking (11–13). Thus, regardless
of origin, mature B-1 cells cannot be looked on simply as
an activated version of B-2 cells, but rather appear to mani-
fest a unique blend of characteristics, some of which are in-
duced in B-2 cells after stimulation.
B-1 cells differ dramatically from B-2 cells in the signals
required to produce cell cycle progression to S phase. On
 
1
 
Abbreviations used in this paper:
 
 Cdk, cyclin-dependent kinase; DTT, dithio-
threitol; GAPDH, glyceraldehyde-6-phosphate dehydrogenase; sIg, surface
immunoglobulin; STAT, signal transducer and activator of transcription. 
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the one hand, sIg cross-linking by anti-Ig Ab, which drives
B-2 cells to incorporate thymidine, fails to similarly stimu-
late B-1 cells (14, 15). This failure appears to result from a
block in sIg-mediated signal transduction at the level of
phospholipase C
 
g
 
2 activation, and in this respect B-1 cells
appear to be hyporesponsive in comparison with B-2 cells
(16). On the other hand, treatment with phorbol ester alone
drives B-1 cells to enter S phase, whereas phorbol ester fails
to similarly stimulate B-2 cells (14, 15, 17). Instead, B-2 cells
are stimulated by phorbol ester only in combination with a
calcium ionophore, so in this respect B-1 cells appear to be
hyperresponsive. B-1 cell hyperresponsiveness to phorbol
ester treatment is further manifested in the rapidity with
which S phase is attained; peak thymidine incorporation
occurs 24–30 h after B-1 cells are stimulated with PMA,
but 54–60 h after B-2 cells are stimulated with PMA plus
ionomycin (or with anti-Ig or LPS [14, 15]). The origin of
the very rapid progression to S phase of phorbol ester–stimu-
lated B-1 cells has not been clarified.
We investigated whether the rapid cell cycle progression
observed in B-1 cells responding to PMA is accompanied
by altered expression of cell cycle regulatory gene products,
in particular the G1 cyclins. Cyclins are growth factor in-
ducible proteins that regulate cell cycle progression by asso-
ciating with a group of serine/threonine kinases, the cyclin-
dependent kinases (Cdks [18]). A subgroup of cyclins, the
D-type cyclins (D1, D2, and D3), are involved in regulat-
ing the G1 phase of the cell cycle, and their expression ap-
pears to be rate-limiting for G1 phase progression (19–26).
Complexes containing D-type cyclins and either Cdk4 or
Cdk6 function in part by phosphorylating members of the
retinoblastoma gene product (Rb) family (27–32). Hyper-
phosphorylation of Rb attenuates its growth-inhibitory
properties, thereby allowing cells to progress into the late
G1 phase of the cell cycle (33, 34). To elucidate the unusu-
ally swift response of B-1 cells to phorbol ester alone, we
analyzed the timing of cyclin D expression. We found that
phorbol ester induces unusually early expression of cyclin
D2 in B-1 but not B-2 cells, that this early-expressed cyclin
D2 associates with Cdk4, and that this correlates with as-
sembly of active kinase complexes and phosphorylation of
Rb at the Cdk4 phosphoacceptor Ser
 
780
 
 site.
 
Materials and Methods
 
Animals.
 
Male BALB/cByJ mice at 8–14 wk of age were ob-
tained from The Jackson Laboratory. Mice were housed at least 1 wk
before experimentation. Mice were cared for and handled at all
times in accordance with National Institutes of Health and insti-
tutional guidelines.
 
B Cell Purification.
 
B-1 and B-2 lymphocytes were prepared
by negative selection from peritoneal washout cells and from
spleen cell suspensions, as described previously (35). The resulting
B cells were cultured at 37
 
8
 
C with 5% CO
 
2
 
 in RPMI 1640 me-
dium (BioWhittaker) supplemented with 5% heat-inactivated fe-
tal bovine serum (Sigma Chemical Co.), 10 mM Hepes (pH 7.2),
50 
 
m
 
M 2-ME, 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, and
100 
 
m
 
g/ml streptomycin. B-1 cells were 90–96% sIgM
 
1
 
, CD5/
Mac-1
 
1
 
 by flow cytometric analysis.
 
Immunoprecipitation.
 
B cells were lysed by incubation for 30
min (4
 
8
 
C) in ice-cold NP-40 buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 20 mM EDTA, 0.5% NP-40, 1 mM PMSF, 25 
 
m
 
g/
ml leupeptin/aprotinin, 1 mM Na
 
3
 
VO
 
4
 
, and 10 mM 
 
b
 
-glycero-
phosphate) (22). Insoluble material was removed by centrifuga-
tion at 15,000 
 
g
 
 for 15 min (4
 
8
 
C). Cell lysates were then incu-
bated for 3 h with 1.5 
 
m
 
g nonimmune IgG or 1.5 
 
m
 
g anti-Cdk4
Ab, or 1.5 
 
m
 
g anti-Cdk6 Ab, followed by the addition of 50 
 
m
 
l of
a 1:1 slurry of protein G–agarose. After 90 min, the immune com-
plexes were collected, washed several times in NP-40 buffer, and
separated by electrophoresis through a 10% polyacrylamide SDS
gel. The resulting proteins were then transferred to Immobilon-P
membrane (Millipore) and immunoblotted with an anti-cyclin
D2 mAb (1:500 dilution in TBST) as described below.
 
Immunoblotting.
 
For detection of cyclin D2, cyclin D3, and
retinoblastoma, B lymphocytes were solubilized in 100 
 
m
 
l of sol-
ubilization buffer (50 mM Hepes, pH 7.4, 15 mM EGTA, 137 mM
NaCl, 15 mM MgCl
 
2
 
, 0.1% Triton X-100, 10 mM 
 
b
 
-glycero-
phosphate, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM PMSF, and 1 
 
m
 
g/ml aproti-
nin/leupeptin) and NP-40 buffer supplemented with 20 mM
NaF, respectively (36). Insoluble material was removed by cen-
trifugation at 15,000 
 
g
 
 (15 min), and 10–20 
 
m
 
g of total protein
was separated through a 12% polyacrylamide SDS gel and trans-
ferred to Immobilon-P membrane. The Immobilon-P membrane
was blocked in TBST (20 mM Tris, pH 7.6, 137 mM NaCl, and
0.1% Tween-20) containing 5% nonfat dry milk (4 h), washed
several times, and then incubated 18 h with specific primary Abs.
The membrane was washed extensively with TBST, incubated
with anti–rabbit or mouse IgG-conjugated horseradish peroxi-
dase Ab at 1:3,000 in TBST (90 min), and developed by enhanced
chemiluminescence.
 
In Vitro Rb Kinase Assay.
 
B cells were sonicated at 4.0
 
8
 
C in Rb
buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA,
2.5 mM EGTA, 1 mM dithiothreitol [DTT], 0.1% Tween-20,
10% glycerol, 0.1 mM PMSF, 1 
 
m
 
g/ml leupeptin/aprotinin, 10
mM 
 
b
 
-glycerophosphate, 1 mM NaF, and 0.1 mM Na
 
3
 
VO
 
4
 
)
(28). Insoluble material was removed by centrifugation, and the
supernatant was incubated with 1.5 
 
m
 
g nonimmune rabbit IgG or
1.5 
 
m
 
g anti-cyclin D2 Ab. After 3 h, 50 
 
m
 
l of a 1:1 slurry of pro-
tein G–agarose was added and incubated for an additional 60 min.
The immune complexes were then washed six times with Rb
buffer and three times in a buffer of 50 mM Hepes, pH 7.4, and
1 mM DTT. The immune complexes were resuspended in 30 
 
m
 
l
of kinase buffer (50 mM Hepes, pH 7.5, 10 mM MgCl
 
2
 
, 5 mM
MnCl
 
2
 
, 1 mM DTT, 2.5 mM EGTA, 10 mM 
 
b
 
-glycerophos-
phate, 0.1 mM Na
 
3
 
VO
 
4
 
, and 10 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP at 6,000 Ci/
mmol) in the presence of 1 
 
m
 
g of a truncated Rb protein substrate
(p56
 
Rb
 
). The reactions were terminated after 15 min at 30
 
8
 
C by
the addition of 2
 
3
 
 SDS sample buffer, and the kinase mixture was
separated through a 10% polyacrylamide SDS gel. Phosphorylated
Rb was detected by autoradiography of the dried gel.
 
Northern Blot Analysis.
 
Total RNA was isolated from primary
B cells (Ultraspec RNA reagent; Biotecx Laboratories, Inc.), size
fractionated by denaturing agarose gel electrophoresis, and trans-
ferred to GeneScreen Plus membranes (NEN Life Science Products,
Inc.). Membranes were hybridized with radiolabeled cDNA probes
specific for cyclin D2 and glyceraldehyde-6-phosphate dehydrog-
enase (GAPDH), generated by PCR using previously reported
primer sequences (37, 38), and developed by autoradiography.
 
Reagents.
 
F(ab
 
9
 
)
 
2
 
 fragments of goat anti–mouse IgM were
obtained from Jackson ImmunoResearch Laboratories and used
at 15 
 
m
 
g/ml. PMA was obtained from Sigma Chemical Co. and
used at 300 ng/ml. Percoll was obtained from Amersham Phar- 
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macia Biotech. Anti–rabbit and anti–mouse IgG-conjugated horse-
radish peroxidase Abs, anti-cyclin D2 Ab (sc-452), and anti-Cdk4
Ab (sc-260) were obtained from Santa Cruz Biotechnology.
Anti-Cdk6 Ab (13446E) was obtained from PharMingen. The
production of mouse anti-cyclin D2 Ab (DCS-3 and DCS-5) and
mouse anti-cyclin D3 Ab (DCS-22), used for immunoblotting,
has been described (39, 40). Antiactin Ab was obtained from
Sigma Chemical Co. Rb phosphoserine
 
780
 
–specific Ab was ob-
tained from MBL International Corp. (41). The truncated Rb
substrate protein (p56
 
Rb
 
) was obtained from QED Advanced
Research Technologies. Enhanced chemiluminescence reagents
were obtained from Kirkegaard & Perry. Protein G–agarose was
obtained from Life Technologies.
 
Results
 
To investigate intrinsic differences between B-1 and B-2
proliferative responses to phorbol ester, we evaluated the ex-
pression of D-type cyclin regulators, which function to cou-
ple mitogenic pathways to cell cycle regulatory Cdks in a
number of divergent cell types (18). Because we previously
identified cyclin D2 as the major D-type cyclin expressed in
anti-Ig and LPS mitogenically activated mature B-2 lympho-
cytes, we initially focused on this G1 cyclin (36).
B cells were treated with the phorbol ester PMA or anti-Ig
for various periods of time, after which solubilized proteins
were size fractionated by SDS-PAGE and immunoblotted
with an mAb that specifically recognizes cyclin D2 (39).
Stimulation of B-2 cells with anti-Ig produced substan-
tial upregulation of cyclin D2 expression, which peaked at
24 h, as shown in Fig. 1 and as reported previously (36). In
contrast, PMA treatment of B-2 cells, which fails to in-
duce S phase entry, failed to produce any detectable in-
crease in cyclin D2 (Fig. 1). The results with B-1 cells were
completely inverted. Stimulation of B-1 cells with anti-Ig,
which fails to induce S phase entry, failed to produce a sub-
stantial increase in cyclin D2 (data not shown). However,
PMA treatment of B-1 cells produced marked induction of
cyclin D2 expression (Fig. 1 A). The PMA-induced in-
crease in cyclin D2 occurred quite early, reaching a peak
within 2–4 h of treatment, much sooner than the onset of
cyclin D2 expression in anti-Ig–stimulated B-2 cells, and
significantly earlier than inducible cyclin D2 expression ob-
served in other cells of hematopoietic origin (20, 23, 42).
By 14 h, the level of cyclin D2 in PMA-stimulated B-1
cells had significantly declined although it was still readily
detected as B-1 cells entered S phase.
PMA stimulation also produced an increase in cyclin D3
expression, but this occurred much later (at 14–24 h) and
took place in both B-1 and B-2 cells (Fig. 1 B). Much of
the delayed increase in cyclin D3 would appear to be too
late to control B-1 G1-S transition, inasmuch as entry into
S phase occurs at 18 h and peak S phase is found at 24–30 h
of PMA stimulation (14, 15). Cyclin D1 expression was not
stimulated by PMA in B-1 or B-2 cells (data not shown).
These findings indicate that cyclin D2 induction accu-
rately reflects the divergent mitogenic responses of B-1 and
B-2 cells, and strongly suggest that early cyclin D2 expres-
sion is a key feature of the B-1 cell S phase response to
phorbol ester stimulation.
To determine whether the early induction of cyclin D2
depends on new protein synthesis and/or new gene expres-
sion, B-1 cells were treated with PMA in the presence or
absence of cycloheximide and actinomycin D for 4 h. As
shown in Fig. 2 A, both cycloheximide and actinomycin D
completely blocked cyclin D2 expression induced by
PMA. These results suggest that cyclin D2 expression in
PMA-treated B-1 cells is regulated at the level of transcrip-
tion. This conclusion is supported by Northern blot analy-
sis showing marked induction of cyclin D2 mRNA expres-
sion after B-1 cell stimulation with PMA for 1 (data not
shown) and for 2 h (Fig. 2 B).
To evaluate whether the early transcriptional induction
of cyclin D2 is accompanied by the formation of cyclin
D2–Cdk4 or cyclin D2–Cdk6 holoenzyme complexes, B-1
and B-2 cells were treated with PMA or anti-Ig for various
Figure 1. Cyclin D2 expression is induced early and uniquely in B-1
lymphocytes treated with PMA. (A) Primary B-1 and B-2 lymphocytes
were cultured in the presence of medium alone (Med) or were stimulated
with PMA (300 ng/ml) for 1, 2, 4, 14, and 24 h. As a control, parallel
cultures of B-2 cells were treated with anti-Ig for 24 h. At the indicated
times, cells were lysed in a 0.1% Triton X-100 buffer, and 10 mg protein
was then resolved by 10% SDS-PAGE, transferred to Immobilon-P
membrane, and immunoblotted with a cyclin D2–specific mAb. The
position of cyclin D2 is indicated by the arrow on the right. (B) B-1 and
B-2 cells were stimulated as indicated, after which cellular proteins were
immunoblotted for expression of cyclin D3, as described above. The po-
sition of cyclin D3 is indicated by an arrow.
Figure 2. Induction of cyclin
D2 expression in B-1 cells is
regulated by transcription and
translation. (A) Primary B-1 lym-
phocytes were cultured for 4 h
in medium alone (Med) or in
medium containing PMA at 300
ng/ml in the presence or absence
of actinomycin D (ActD) at 500
ng/ml or cycloheximide (CHX)
at 10 mg/ml. B cells were then
collected and lysed in a 0.1%
Triton X-100–containing solu-
bilization buffer. Cellular proteins (10 mg) were resolved by 10%
SDS-PAGE, transferred to Immobilon-P membrane, and immunoblotted
with a cyclin D2–specific mAb as described in Materials and Methods. (B)
Primary B-1 lymphocytes were cultured for 2 h in medium alone (Med)
or in medium containing PMA at 300 ng/ml, after which total RNA was
extracted, resolved by denaturing agarose gel electrophoresis, and North-
ern blotted for expression of cyclin D2 and GAPDH as described in
Materials and Methods. The positions of cyclin D2 and GAPDH mRNA
are indicated by arrows. 
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periods of time, after which extracted protein was immuno-
precipitated with rabbit anti–mouse Cdk4 or rabbit anti–
mouse Cdk6, resolved by SDS-PAGE, and immunoblotted
for cyclin D2. As shown in Fig. 3, the assembly of cyclin
D2–Cdk4 complexes essentially paralleled the inducible ex-
pression of cyclin D2 (see Fig. 1): cyclin D2–Cdk4 com-
plexes were readily detected in PMA-stimulated B-1 cells
within 4 h; however, cyclin D2–Cdk4 complexes were not
detected after anti-Ig stimulation of B-1 cells. Conversely,
cyclin D2–Cdk4 complexes were readily observed in anti-
Ig–stimulated B-2 cells, but were not found after B-2 stimu-
lation with PMA. The formation of cyclin D2–Cdk6 com-
plexes was similarly addressed: assembly of these complexes
recapitulated that of cyclin D2–Cdk4 complexes although
the former were much less abundant than the latter. Indeed,
total Cdk4 levels exceeded Cdk6 levels in both B-1 and B-2
cells (data not shown). Notably, the observed associations
between cyclin D2 and Cdk4, and between cyclin D2 and
Cdk6, are specific inasmuch as no immunoreactive protein
corresponding to the expected cyclin D2 molecular weight
of 34 kD was detected after immunoprecipitation with (con-
trol) nonimmune serum alone (data not shown). These re-
sults indicate that cyclin D2 expression in B-1 cells is accom-
panied by the formation of Cdk-containing complexes.
To evaluate the physiological significance of PMA-stim-
ulated cyclin D2 expression and cyclin D2–Cdk4/Cdk6 as-
sembly in B-1 cells, the capacity of immunoprecipitated
cyclin D2 to phosphorylate exogenous Rb in vitro was as-
sessed. As shown in Fig. 4 A, treatment of B-1 cells with
PMA produced kinase-active, D2-containing complexes
within 4 h, whereas treatment of B-2 cells with PMA failed
to produce immunoprecipitable kinase activity. Further,
B-1 cell stimulation with PMA resulted in phosphorylation
of endogenous Rb within 4 h, as evidenced by the appear-
ance of more slowly migrating species (pRb) detected by
immunoblotting with anti-Rb antisera (data not shown).
Moreover, endogenous Rb phosphorylation was due, at least
in part, to cyclin D–Cdk4 complexes, because the cyclin
D–Cdk4 phosphoacceptor Ser
 
780
 
 site was phosphorylated
within 4 h and the extent of this phosphorylation increased
 
steadily over time, as measured by an anti-pRb Ser
 
780
 
 Ab
(Fig. 4 B). Of note, Rb Ser
 
780 
 
phosphorylation was not de-
tected in B-1 cells treated with anti-Ig alone. Collectively,
these results indicate that cyclin D2 is induced early by
PMA in B-1 cells, and that induced cyclin D2 is capable of
association with Cdks to constitute enzymatically active
complexes; these results strongly suggest that cyclin D2–
Cdk4 and to a lesser extent cyclin D2–Cdk6 complexes are
involved in regulating PMA-mediated cell cycle progres-
sion in B-1 lymphocytes.
 
Discussion
 
We examined D-type cyclin expression in B-1 cells to elu-
cidate the mechanism underlying the rapid onset of S phase
produced by stimulation with phorbol ester alone. In keep-
ing with previous results, cyclin D2 was found to be the
major D-type cyclin induced by proliferative signals in B-1
and B-2 cells. PMA induced cyclin D2 early (at 2–4 h) in
B-1 cells but not at measurable levels in B-2 cells, whereas
in direct contrast, anti-Ig induced cyclin D2 late (at 24 h)
in B-2 cells with little, if any, expression detectable in B-1
cells (data not shown). The phorbol ester–induced expres-
sion of cyclin D2 in B-1 cells is controlled at the level of
transcription inasmuch as the PMA-stimulated increase in
cyclin D2 protein (a) was blocked by actinomycin D, and
(b) was accompanied by a rapid increase in cyclin D2
mRNA. Cyclin D3 was also induced after PMA stimula-
tion, but this occurred much later and in both B-1 and B-2
cells. Thus, cyclin D2 expression appears to be an accurate,
consistent, and early reflection of the competency of partic-
ular stimuli to induce cell cycle progression to S phase in
discrete primary B cell populations. Moreover, the ease and
rapidity with which a key cell cycle control protein is
induced in B-1 cells may be causally related to the self-
renewing characteristics of this B cell subset as well as its
propensity for clonal and malignant transformation (1–6).
Figure 3. Cyclin D2–Cdk4 complexes are formed in response to PMA
stimulation in B-1 cells. B-1 and B-2 lymphocytes were cultured in me-
dium alone (M) or in medium containing PMA at 300 ng/ml or anti-Ig at
15 mg/ml (Ig), for the indicated times. Nondenaturing NP-40 detergent
extracts were prepared and sequentially immunoprecipitated with 1.5 mg
of nonimmune serum, 1.5 mg of anti-Cdk4 Ab, and 1.5 mg of anti-Cdk6
Ab. The resulting immune complexes were then resolved by 10% SDS-
PAGE, transferred to Immobilon-P membrane, and probed with anti-
cyclin D2 mAb as described in Materials and Methods. The position of
cyclin D2 (D2) is indicated by the arrows on the right.
Figure 4. Cyclin D2–contain-
ing complexes produced by PMA
treatment of B-1 cells are active,
Rb-phosphorylating kinases. (A)
B-1 and B-2 cells were cultured
in medium alone (M) or in me-
dium containing PMA at 300 ng/
ml (P) for 4 h, after which non-
denaturing Tween-20 detergent
lysates were prepared and immu-
noprecipitated with anti-cyclin
D2 Ab. Immune complexes were
recovered and assayed for in vitro
kinase activity using a truncated
p56Rb protein substrate as de-
scribed in Materials and Methods.
The position of p56Rb is indi-
cated. (B) B-1 cells were cultured
in medium alone (Med), medium containing PMA at 300 ng/ml, or me-
dium containing anti-Ig at 15 mg/ml (Ig), for the indicated times, and then
solubilized in NP-40 lysis buffer. 20 mg of protein was separated by 10%
SDS-PAGE, transferred to Immobilon-P membranes, and then immuno-
blotted with an anti-pRb Ser780 Ab to detect phosphorylation of endoge-
nous Rb at the cyclin D–Cdk4 phosphoacceptor Ser780 site (reference 38). 
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The unexpected induction of cyclin D2 by PMA alone,
uniquely in B-1 cells, provides a molecular basis for the ob-
servation that PMA-stimulated B-1 cells progress to S phase
entry, and this is supported by the demonstration that
PMA-stimulated cyclin D2 associates with Cdk4 and results
in the early appearance of Rb-phosphorylating activity.
The induction of kinase-active cyclin D2–containing com-
plexes in PMA-responsive B-1 cells provides an important
demonstration that only mitogenic signals induce holoen-
zyme formation, in this case exemplified by B cell subsets
that respond differently to the same stimuli. This greatly
strengthens the role of cyclin D2–Cdk4 complex formation
in B cell cycle progression, previously documented by
treating B-2 cells with various stimuli that produce mito-
genesis, such as anti-Ig, LPS, and PMA plus ionomycin
(36, 43–45).
It has been reported elsewhere that cyclin D2 is ex-
pressed early after murine splenic B cell (B-2 cell) stimula-
tion (46). We do not find this to be so; instead, we find that
the timing of cyclin D2 expression anticipates the timing of
the S phase peak by 
 
z
 
24 h in both B-1 and B-2 cells (14,
15). The origin of the disparity in these sets of results re-
mains uncertain, although it should be noted that in the
study by Howard and colleagues, large, rather than small,
B-2 cells were examined, which may reflect prior activa-
tion (46). However, the results we obtained are not simply
a function of large size, inasmuch as there was little induc-
tion of cyclin D2 in B-1 cells stimulated by anti-Ig in our
study (data not shown).
Our earlier observation that B-1 cells progress in cell cy-
cle to S phase in response to phorbol ester treatment,
whereas B-2 cells require treatment with a calcium iono-
phore in addition to phorbol ester, gave rise to the idea that
B-1 cells endogenously express some signaling component
or growth-promoting molecule that requires calcium iono-
phore for expression in B-2 cells. This notion is supported
by our finding that B-2 cells stimulated with anti-Ig for 2 d
become responsive to phorbol ester alone (47), further sug-
gesting that a discrete alteration, inducible by sIg signaling
in mature B-2 cells, is responsible for phorbol ester respon-
siveness. The present results suggest that this alteration,
perhaps in the form of an sIg-triggered signaling compo-
nent or growth-promoting molecule that is constitutively
expressed in B-1 cells, relaxes (or fulfills one of) the require-
ments for cyclin D2 expression. Our recent finding that B-1
cells constitutively express nuclear, activated STAT3 that is
triggered by PMA plus calcium ionophore (as well as by
anti-Ig) in B-2 cells (10) suggests that one or more STAT
proteins may play a role in regulating cyclin D2 expression.
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